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This study demonstrates the use of engineered vesicles to reduce perchlorate. 
Specifically, cell-free extracts containing perchlorate reductase and chlorite dismutase 
enzymes were encapsulated in a triblock copolymer vesicle functionalized with the outer 
membrane porin OmpF. The porin allows for perchlorate transport into the vesicles, inside 
which the encapsulated enzymes transform perchlorate to chloride. Perchlorate reduction was 
quantified using a methyl viologen colorimetric technique. The vesicle solutions had 
perchlorate-reducing activities ranging from 35-45 units per liter. This work shows that 
vesicles can provide a mechanism to utilize environmentally-relevant biological enzymes. 
When incorporated into a vesicle, the enzymes could be used outside of environmental 
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Many environmental contaminants can be transformed to innocuous compounds by 
biological enzymes. These contaminants are often poor substrates for growth; to remove 
them cells require that a narrow range of environmental conditions be maintained. 
Maintaining appropriate conditions represents a significant amount of engineering effort for 
many biological treatment systems [1]. For example, engineered systems that utilize biomass 
for the treatment of perchlorate must add excess electron donor to reduce preferred electron 
acceptors such as nitrate and oxygen before perchlorate is reduced [2]. To remove biological 
oxygen demand (BOD), activated sludge treatment requires pumping of large amounts of 
oxygen to maintain aerobic conditions. Activated sludge also creates large amounts of excess 
biomass which requires disposal through incineration, land application, or landfilling [3,4]. 
To remove more recalcitrant compounds than BOD, some have suggested that genetic 
modifications could be used to create new metabolic pathways to remove these compounds. 
These techniques could also be used to expand the range of conditions in which cells can 
grow [5,6]. However, current regulations generally do not allow the release of genetically 
modified bacteria into the environment, as the modified genetic material could be spread in 
an uncontrolled manner by bacterial cells [7]. Due to their versatility, biological cells have 
applications to many environmental engineering systems. Nevertheless, they have 
disadvantages that make them less than ideal in certain cases. 
Cells provide cheap, versatile and abundant sources of catalysts to increase the rate of 
reaction of a plethora of reactions. However, the goals of an engineer and the goals of the cell 
are quite different. Whereas the engineer’s goal is to catalyze a reaction, the cell’s goal is to 
replicate itself and pass on its genes. While most of the time both parties can be satisfied, 
they do conflict in some systems, as illustrated above. One solution to these problems is to 
create a simplified version of the cell that performs only one task of interest, regardless of the 
ambient conditions. For an engineer, the ideal biological cell would be a catalyst that 
regenerates itself and does not foul, something like the packet of enzymes shown in Figure 1. 
Enzymes could be encapsulated in some sort of shell and a transmembrane pore would allow 
transport into and out of the vesicle. Several methods have been proposed to create these 
simplified cells, or as they will be known in this work, engineered vesicles. These vesicles 
can still utilize the potency of biomolecules, but as the system is much more defined from an 
engineering perspective than a biological cell, vesicles can obviate many of the shortcomings 
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Many studies have used vesicles formed from lipid membranes (liposomes) to 
investigate how this kind of system could be tailored for different functionalities. However, 
lipids are subject to oxidation over time and liposomes have a limited number of applications 
after 30 or more years of research [11,12]. Unlike lipid membranes, vesicles created from 
polymer-based membranes are stable for long periods of time and are resistant to oxidation, 
making them more suitable for engineering applications [13]. Vesicles constructed from 
biomimetic triblock copolymers have been used to create hybrid abiotic-biotic systems with 
several applications [13,14,10]. Triblock copolymer membranes mimic the structure of lipid 
membranes with hydrophobic groups in the interior of the polymer and exterior hydrophilic 
groups [15]. This lipid bilayer-like structure allows for the functional insertion of membrane 
proteins, as demonstrated with several proteins [16,17]. These membranes are generally 
thicker than their lipid counterparts: a polymer membrane is approximately 10 nm whereas a 
lipid membrane is generally 5 nm. Despite this significant increase in thickness, membrane 
proteins have been shown to functionally insert in the polymer. It is theorized that the 
polymer surrounding the membrane protein compresses to match the size of the protein [18]. 
The polymer generally forms vesicle-like structures with diameters ranging from 50 to 500 
nm [9]. Methacrylate end groups can be incorporated into the triblock structure, and can be 
polymerized under UV light to give additional stability to the vesicles [15]. Applying these 
polymer vesicles to environmental applications is the focus of this work. 
This work explores the advantages of engineered vesicles as compared to traditional 
biological treatment. Specifically, my work attempts to create engineered vesicles with 
encapsulated perchlorate-reducing enzymes and incorporated membrane proteins that allow 
perchlorate transport. To understand how engineered vesicles might be advantageous when 
treating perchlorate, one must first understand issues surrounding current perchlorate 
treatment, bacterial perchlorate enzymes/metabolism and the design of this proposed 
engineered vesicle. These issues are addressed in each of the subsequent sections.  
Perchlorate Toxicity, Regulation and Current Treatment Technologies 
Perchlorate is an environmental contaminant arising from the historical disposal of 
munitions and rocket fuel into the environment, before it was understood that this compound 
had human health effects. It is a thermodynamically strong oxidant, with many uses in the 
aerospace and defense industries. However, at ambient temperatures and pressures, 
perchlorate is very stable in aqueous solution and is almost kinetically unreactive. Perchlorate 
affects iodide uptake by the thyroid gland and can subsequently affect hormone 
production—especially in sensitive subpopulations. There has been significant debate as to 
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the levels at which health effects arise. There is a general consensus that infants and the fetus 
of a pregnant woman are the most sensitive subpopulations for thyroid toxicity, but no 
studies have directly measured the toxic effects of perchlorate on those populations [19].  
As a result of this lack of data, proxies must be used and assumptions made to 
determine an appropriate drinking water standard. To protect sensitive subpopulations, the 
EPA in 2002 suggested that perchlorate should be treated to below 1 µg/L in drinking water, 
based on a rat model [20]. Other studies have reported that concentrations as high as 180 and 
220 µg/L in drinking water would be required to have an effect on iodide uptake in adult 
humans, and no effect on hormone production is observed until even higher concentrations of 
perchlorate are reached [21]. In 2005 the National Academy of Science used the data in [21] 
and an uncertainty factor of 10 (to account for sensitive subpopulations) when proposing an 
equivalent drinking water standard of 24.5 µg/L [22,19]. Many states have also proposed 
limits for perchlorate in drinking water, varying from 1-18 ppb [19]. The wide variety of 
proposed drinking water standards is a reflection of the wide variety of methodologies used 
to support them. At present, no national standard exists [19]. Nevertheless, perchlorate is 
detectable in the drinking water of 16 million Americans [23] and may constitute a 
significant health concern [24,25]. 
Over 15.9 million kg of perchlorate have been released into the environment due to 
rocket and missile use [26]. Before 1997, it was difficult to detect the environmental fate of 
these 15.9 million kg, as perchlorate could not be reliably detected below 400 ug/L. In 1997, 
a new analytical method became available with a detection limit of 4 ug/L, and perchlorate 
contamination was quickly determined to be widespread. Subsequently, the EPA published a 
draft risk assessment concerning perchlorate. In 2002 the EPA released a revised risk 
assessment for public comment and peer review, and in 2003 the EPA, Department of 
Defense, NASA and Department of Energy asked the National Academy of Science (NAS) to 
review the draft risk assessment after disagreement about the proposed reference dose. In 
January 2005, an NAS report concluded that existing studies did not support a link between 
perchlorate exposure and developmental effects and proposed raising the perchlorate 
reference dose and drinking water standard from 1 ug/l to 24.5 ug/L [19]. The EPA adopted 
the National Academy of Science’s proposed reference dose in January 2005 [22], but in 
October 2008 made a preliminary decision not to establish a national drinking water standard. 
The EPA stated that regulating perchlorate would not provide a “a meaningful opportunity 
for health risk reduction for persons served by public water systems [27].” At the same time, 
the agency proposed a interim health advisory value of 15 ug/L [27]. After the transition from 
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the Bush Administration to the Obama Administration, the EPA asked the NAS to reevaluate 
the interim health advisory value. As the agency is reconsidering its previous positions, a 
national drinking water standard may be possible in the future [28,29]. If a national standard 
were enacted, demand for perchlorate treatment technologies would increase greatly. 
However, many water treatment utilities are treating perchlorate voluntarily due to perceived 
health effects and public demand. As health concerns grow, even in the absence of a national 
standard, demand for perchlorate treatment technologies may increase.  
Viable abotic and biotic technologies exist for perchlorate treatment to meet proposed 
limits, but all have shortcomings that would hinder their widespread implementation. 
Example abotic systems include: ion exchange [30], reverse osmosis [31], electrodiaylsis 
removal (EDR) [32], and granular activated carbon (GAC) [33]. These abiotic technologies 
utilize adsorption or diffusion-limited filtration to remove perchlorate from bulk solution. 
These technologies concentrate perchlorate, but do not remove it from the environment. This 
creates a brine solution with elevated salinity and perchlorate levels. This brine must be 
further treated either chemically or biologically. Biotic processes require an exogenous 
electron donor to reduce perchlorate to chloride and oxygen. However, microbes will utilize 
oxygen and nitrate as electron acceptors before perchlorate is utilized and thus biotic 
processes must remove alternative electron acceptors before perchlorate is utilized [2].  
The most commonly used process for ex situ perchlorate removal is ion exchange. Ion 
exchange is a physical-chemical process in which ions on a solid surface are exchanged for 
ions of similar size and charge. In the case of perchlorate, chloride is often exchanged for 
perchlorate using specialized media. Ion exchange media has a limited capacity and must be 
regenerated when exhausted. This is achieved using a backwash solution with high salt 
concentrations, which replaces the perchlorate with another anion. This creates a salty 
solution highly enriched in perchlorate. Membrane technologies are another common method 
of treating perchlorate. Electrodialysis reversal uses electric current to drive perchlorate and 
its accompanying cation across selective membranes and into a brine solution. Reverse 
osmosis uses high osmotic pressures to drive water across a semipermeable membrane, 
creating a permeate solution mostly free of perchlorate, and a brine solution enriched in 
perchlorate and other electrolytes that were present in the source water. All of the brine 
solutions created by these processes require further treatment [34]. 
Ex situ treatment using a bioreactor places perchlorate-laden water in contact with 
microbes capable of degrading perchlorate to chloride. The reduction of perchlorate to 
chloride requires the addition of electron donor, usually in the form of acetic acid, ethanol, 
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methanol or hydrogen. Other nutrients such as ammonia or phosphorous may be added if the 
source water alone cannot support the growth of organisms. Common bioreactor 
configurations are fluidized-bed reactors and fixed-bed reactors. In both configurations, 
microbes grow on some kind of media: either sand, granular activated carbon, or plastic 
media. Fluidized beds pump water through at a high enough rate to suspend the media, 
whereas a fixed-bed utilizes static media. Fluidized beds can provide greater surface area for 
microbes and thus a smaller reactor volume, but this requires higher pumping rates. If 
alternative electron acceptors like nitrate or oxygen are present, the microbes will 
preferentially utilize those and not degrade perchlorate. Thus, control of the influent nitrate 
and dissolved oxygen concentrations is vital for successfully operation of 
perchlorate-reducing bioreactors. To prevent clogging of the reactor from microbial growth, 
backwashing at high flow rates is used to remove excess biomass. This prevents flow 
channeling, short-circuiting and high headloss across the reactor [34]. 
An interesting union of these technologies exists in the BIOBROxTM (Biodestruction 
of Blended Residual Oxidants) process. In this process, drinking water from a contaminated 
source is treated with ion exchange, electrodialysis reversal, or reverse osmosis and the brine 
is then treated with a bioreactor. However, the source of electron donor for the brine is 
municipal wastewater. Instead of using an expensive consumable like acetic acid for an 
electron donor, a waste product is utilized and treated. Additionally, enough wastewater is 
blended to reduce the salinity of the brine to a level that non-halophilic bacteria can tolerate. 
The process has been implemented at full-scale in a 3.75 million gallon per day facility and is 
operated by Magna Water District in Magna, Utah. The effluent from this process can then be 
safely discharged to the sewer or put into a reuse system [35]. 
Bacterial Perchlorate Metabolism 
Two principle enzymes have been implicated in the reduction of perchlorate to 
chloride: perchlorate reductase and chlorite dismutase. Perchlorate reductase (Pcr) catalyzes 
the reduction of perchlorate to chlorate and from chlorate to chlorite as illustrated in Figure 2. 
Both of these reactions require an external source of reducing power, usually in the form of 
an exogenous electron donor [25]. Pcr is a 420 kDa protein believed to be a trimer of 
heterodimers (a3b3) containing iron, molybdenum and selenium [36]. The Pcr protein is found 
in the periplasm of perchlorate-reducing bacteria, but it is a soluble protein [25]. Chlorite 
dismutase (Cld) then catalyzes the dismutation of chlorite into chloride and O2 (Figure 2). As 
this is a dismutation reaction, no external electron donor is required in this step. Cld is a 
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is described in more detail below. The membrane is a biomimetic ABA triblock copolymer 
with hydrophobic interior groups and hydrophilic exterior groups, which can support inserted 
membrane proteins such as OmpF. In this work, the perchlorate-reducing enzymes were 
supplied in a cell-free extract and encapsulated in the interior of the vesicle. The reducing 
power for these reactions was provided by methyl viologen. 
OmpF has been used in previous encapsulation studies to transport ions across a 
triblock copolymer membrane [9,14]. This protein is a homotrimer of 37 kDa subunits 
proteins, and each protein subunit contains a 600 dalton pore that allows small solutes in and 
out of the membrane via passive transport/diffusion. The pore has a slight cation specificity, 
but anions such as perchlorate can be transported through the pore [44]. OmpF was chosen as 
it has been used before in similar studies and is large enough to allow the passage of the 
materials of interest. Enzymes targeted to a specific compound (perchlorate in this case) can 
be encapsulated inside a vesicle and coupled to transport proteins (such as OmpF) that allow 
the influx of that compound and the efflux of break-down products. This system thus 
represents a novel means of utilizing environmentally-relevant enzymes, protecting them in a 
polymer shell and coupling them to transport processes. Unlike a cell, this system does not 
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Utilizing NIS has not been attempted in this work due to the difficulty of purifying 
eukaryotic membrane proteins and incorporating them into a polymer membrane. In addition 
to the difficult task of purifying and incorporating NIS, a source of reducing power must be 
provided for the encapsulated perchlorate-reducing enzymes to function. Unlike the 
OmpF-based vesicles, which used methyl viologen as a source of reducing power, NIS-based 
vesicles will not be permeable to methyl viologen. The incorporation of an additional protein 
into the membrane or encapsulation of a system for generating reducing power may be 
necessary to allow for electrons/reducing power to be shuttled inside the vesicle. 
Results of this Study 
My results show that polymer vesicles with encapsulated perchlorate-reducing 
enzymes and membrane-incorporated OmpF can reduce perchlorate. Using these engineered 
vesicles, perchlorate will be reduced at enzymatic rates whenever conditions are 
thermodynamically favorable, rather than being subject to the protein expression patterns of 
the cell.   
These vesicles circumvent many of the shortcomings of biological treatment, while 
retaining its advantage of completely reducing perchlorate to chloride at enzymatic rates. 
This approach could also be applied to other enzymes and other contaminants. Conceivably 
any process for which biological treatment is difficult could be distilled into an engineered 
vesicle approach. The relevant enzymes could be purified, placed inside a vesicle with 
membrane proteins and then used to treat recalcitrant compounds. At first, these vesicles will 
have a limited number of high-value applications, as the recombinant enzymes, proteins and 
polymer are difficult to produce, whereas many kinds of cells are simple to grow and 
incorporate into engineered systems. Although this approach would be used in high value 
applications initially, it could become much more widespread as the components become 
easier to produce. 
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MATERIALS AND METHODS 
 
Chemicals and Reagents: The ABA3 was a symmetric poly-(2-methyloxazoline)- 
block-poly-(dimethylsiloxane)-block-poly-(2-methyloxazoline) (PMOXA15-PDMS110- 
PMOXA15) block copolymer and was a generous gift of the Meier lab at the University of 
Basel, Switzerland. This polymer was used for all vesicle studies. A description of the 
synthesis of a similar polymer is described in reference [47]. All other chemicals used were 
of reagent grade.  
Strains and Growth Media: Strain BAA-33 Azospira oryzae and Dechloromonas 
agitata 700666 were obtained from ATCC (ATCC, Manassas, VA). Azospira oryzae was 
grown in mineral media as described [39]. Dechloromonas agitata was grown in mineral 
media as described [48]. Actively growing cultures of both strains were used to create 30% 
glycerol stocks which were stored at -80˚C. 
Growth Curves of Azospira oryzae and Dechloromonas agitata: Azospira oryzae 
and Dechloromonas agitata were grown as described before [39,48]. The strains were 
maintained as glycerol stocks, streaked to nutrient agar and grown at 35˚C for 2 – 3 days. 10 
mL starter cultures were prepared from streak plate colonies and incubated at 35˚C on a 
shaker at 100 rpm. After the starter cultures reached an optical density (at 600 nm) of 0.3, 
growth cultures (10 mL) were inoculated in triplicate with 1 mL of the starter culture for 
growth curves and incubated at 35˚C on a shaker at 100 rpm. Samples were taken from each 
triplicate culture for later chlorate or perchlorate analysis and optical density measurements 
were taken at 600 nm over time. 
Preparation of Cell-Free Extract Containing Perchlorate-Reducing Enzymes: 
Cell extract containing perchlorate reducing enzymes was obtained as described before [49]. 
Azospira oryzae was maintained as a 30 % glycerol stock, streaked to nutrient agar and 
grown at 30˚C for 2 – 3 days. 100 mL starter cultures in mineral media [39] were prepared 
from Azospira streak plates. Upon reaching an optical density (at 600 nm) of ~ 0.6 cultures 
were transferred to 5 L mineral media. After reaching an optical density (at 600 nm) of ~ 0.6, 
the 5 L cultures were pelleted, resuspended in 10 mL 50 mM potassium phosphate buffer (pH 
6.0), and broken using a sonic dismembrator (Fisher Scientific, Waltham, MA). Three five 
minute lysis cycles (3 sec on 2 sec off) were used to break the cells. The lysate was 
subsequently centrifuged at 5,000 x g for 15 min. The resulting supernatant was then 
centrifuged at 140,000 x g for one hour using a Beckman preparative ultracentrifuge 
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(Beckman-Coulter, Fullerton, CA) to obtain a red supernatant enriched in perchlorate 
reductase and chlorite dismutase.  
Expression and Purification of OmpF: Porin proteins were obtained by 
overexpressing and purifying the Escherichia coli outer membrane protein, OmpF from the 
strain BL21(DE3) omp8 [50]. Protein purification was performed as described [14] and 
briefly summarized here. Cultures were inoculated 1:200 from overnight cultures into 1 L 
Luria-Bertani broth and grown to an optical density (at 600 nm) of ~ 0.6. Cultures were then 
induced with IPTG at 0.4 mM for 6 hours. Cells were then pelleted (10,000 x g, 10 min). 
Cells were resuspended in 20 mM Tris-Cl pH 8.0, 2 % SDS and broken using a sonic 
dismembrator (Fisher Scientific, Waltham, MA). Three five minute lysis cycles (3 sec on 2 
sec off) were used to break the cells. The OmpF-containing peptidoglycan layer was pelleted 
by centrifugation (60 min, 40,000 x g). The resulting small black pellet was resuspeneded in 
prextraction buffer (0.125 % octyl-POE, 20 mM phosphate buffer, pH 7.4) and centrifuged to 
remove the membrane fraction (140,000 x g, 40 min). The membrane fraction was 
resuspeneded in extraction buffer (3 % octyl-POE, 20 mM phosphate buffer, pH 7.4) to 
solubilize the OmpF. The remaining membrane fraction was removed by centrifugation 
(140,000 x g, 40 min). OmpF purity was verified using SDS-PAGE. A detailed protocol for 
this procedure can be found in Appendix A. 
Preparation of ABA Vesicles, OmpF Incorporation and Cell-Free Extract 
Incorporation: Block copolymer vesicles were prepared by using the film rehydration 
method. Twelve milligrams of polymer was first dissolved in chloroform (2 ml), and the 
chloroform was evaporated slowly in a rotary vacuum evaporator at room temperature using 
a vacuum of 100 mbar. This formed an even film on the inside of round-bottomed flasks. This 
film was then further dried under a high vacuum (5 mbar) for at least 4 h. 1.5 mL of cell 
extract was then added to the film with alternating vigorous vortexing and periodic sonication 
(of duration 30 s) for several minutes. This mixture was then left stirring for at least 8 h. The 
resulting suspension was extruded once through a 1-um track-etched filter (Nucleopore, 
Whatman), followed by extrusion ten times through a 0.4 or 0.6-um track-etched filter 
(Nucleopore, Whatman) to obtain monodispersed unilamellar vesicles. To incorporate OmpF 
into ABA3 vesicles, varying amounts of an OmpF stock solution (in 20 mM phosphate 
buffer, 3% octyl-POE, pH 7.4) were added during the formation of the polymer vesicles. The 
resulting protein-containing vesicles were purified chromatographically by using a column 
packed with Sepharose 2B (Sigma, St. Louis, MO) or Sephacryl 500-HR (GE Healthcare, 
Waukesha, WI) to remove nonincorporated protein and trace detergent [14]. To quantify any 
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contaminating protein outside the vesicles, the BCA protein assay was used. A more detailed 
protocol for this procedure can be found in Appendix A. 
OmpF Transport Experiments: Two batches of vesicles hydrated in HEPES buffer 
with 2.5 mM carboxyfluorescein were made for OmpF transport experiments. One film was 
hydrated in the presence of OmpF at a 1:200 molar ratio of protein to polymer and one film 
was hydrated in HEPES alone with carboxyfluorescein. These vesicles were extruded and 
size excluded using standard methods as above. A fluorescence plate reader was used to 
measure the fluorescence at an excitation wavelength of 494 nm and an emission wavelength 
of 519 nm of both sets of vesicles in triplicate.  
Perchlorate-Reducing Enzyme Activity Assays: Perchlorate-reducing activity was 
assayed using methyl viologen, as described before [49]. Activity levels were measured by 
monitoring the oxidation of reduced methyl viologen (MV) at 578 nm in anaerobic cuvettes 
(Helma, Müllheim, Germany). The assay mixture (50 mM Tris, pH 7.5, 0.5 mM MV) was 
combined with vesicles and prereduced by a small amount of dithonite (0.2 M). The reaction 
was then started by the addition of 20 uL of perchlorate (.1 M). A more detailed protocol for 
this procedure can be found in Appendix A. 
Analytical Techniques for Chlorate, Perchlorate and Protein Concentrations: 
Chlorate Measurements Using Ion Chromatography: Chlorate concentrations 
were measured using ion chromatography using an Ion Pac AS-18 Hydroxide-Selective 
Anion Exchange column from Dionex on a Dionex ICS-2000 system (Dionex, Sunnyvale, 
CA) using 65 mM KOH eluent and a 1.2 mL/min eluent flow rate. Information on this 
method can be found in reference [51]. 
Perchlorate Measurements Using HPLC MS: Perchlorate concentrations were 
measured using high performance liquid chromatography in tandem with mass spectrometry. 
A Waters IC-Pak Anion HR (4.6 x 75 mm) column preceded by a Waters IC-PAK Anion 
guard column (Waters, Milford, MA) was used to prepare samples for injection onto the mass 
spectrometer. The eluent was 50 % 100 mM ammoium formate and 50% acetonitrile at a 
flow rate of 0.5 mL/min on an anionc column. Perchlorate was detected at an m/z ratio of 
99.5 on the mass spectrometer. Additional details about the method can be found in reference 
[52].  
Protein Measurements: Protein concentrations were measured using the BCA kit 
(Pierce, Rockford, IL). 
Construction of pSPOmpF and Expression: The ompF gene was PCR amplified 
from Escherichia coli strain ME9062 using the primers OmpF1 and OmpR1 (Table 2). Both 
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primers were constructed using a segment of the ompF sequence with an NdeI site 
engineered into the upstream primer and the XhoI site engineered into the downstream 
primer with 3 base pairs at the end to allow for restriction digestion. The pET 28b(+) vector 
and the resulting ompF were double digested with NdeI and XhoI. A 3:1 molar ratio of insert 
to vector was used to insert the amplicon into the vector, which was then transformed into 
XL-10 for plasmid maintenance. The plasmid was sequenced and shown to be free of errors 
(data not shown). Protein expression was achieved by transforming the resultant vector into 
BL21 (DE3) and inducing with 1 mM IPTG. 
Construction of pSPNIS and Expression: The rNIS plasmid was a gift from the 
Carrasco group. The rNIS plasmid contains the sequence of the sodium iodide symporter 
from Rattus norvegicus. NIS was PCR amplified from this template. Similar to ompF, 
primers were designed to add NdeI and XhoI sites to NIS for insertion into pET 28b(+) 
(Table 2). The plasmid and amplicon were double digested with NdeI and XhoI. Ligation was 
performed with a 3:1 molar ratio of insert to vector, which was then transformed into XL-10 
for plasmid maintenance. The plasmid was sequenced and shown to be free of errors. Protein 
expression was achieved by transforming the resultant vector into BL21 (DE3). Cultures 
were inoculated 1:200-1:1000 from overnight cultures into Luria-Bertani broth and grown to 
an optical density (at 600 nm) of ~ 0.6. Cultures were then induced with IPTG at 1 mM. Cells 
were then pelleted at various time points (10,000 x g, 10 min). 
Histidine-Tagged Western Blot: Standard techniques were used for running SDS 
PAGE gels [53]. Western blots were performed by transferring from a SDS PAGE gel to 
either a nitrocellulose or PVDF membrane overnight at 17V at 4°C. Membranes were 
blocked for 1 hour in 30 mL of Tris-Buffered Saline Tween-20 (TBST) with 1.5% dry milk. 
Membranes were then incubated at a ratio of 1:4000 Anti His6+-Perxoidase (2) (Roche, Basel, 
Switzerland) to TBST with 0.5% dry milk solution for 1.5 hour. Membranes were 
subsequently washed three times for 5 minutes each with TBST. Membranes were developed 
with BCIP/NBT substrate (Promega, Madison, WI) for 1-5 minutes. 
Protease Experiments for Cell-Extract and Vesicles: Cell extract was digested with 
proteinase K by adding proteinase at 2% of total protein to cell extract and incubating 
overnight at 37°C. Perchlorate-reducing activity was measured before and after digestion. 
Vesicles were digested with proteinase K by adding 5% (v:v) 20 mg/mL proteinase K 
solution (Roche). Vesicles were then incubated for 4 hours at room temperature and size 
excluded. 
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Transmission Electron Microscopy: These measurements were conducted on 
vesicle samples by using a Philips 400 microscope (Philips). The samples were prepared by 
dilution up to 1,000 times and then stained with 2% uranyl acetate on plasma-treated copper 
grids.  
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Table 1 – Strains and Plasmids Used 
Strains: Description: Reference: 
Escherichia coli:   
Omp8 OmpF overexpression strain, AmpR [50] 
ME9062 ompF PCR template  [54] [55] 
XL10 Ultracompetent cells Stratagene 
BL21 (DE3) pET system overexpression Strain Stratagene 
BL21 (DE3) pSPOmpF OmpF overexpression strain, KanR This study 
BL21 (DE3) pSPNIS NIS overexpression strain, KanR This study 
Other bacteria:   
Dechloromonas agitata strain 
CKB 
Perchlorate reducing bacterium [48] 
Azospira oryzae strain PS Perchlorate reducing bacterium [39] 
   
Plasmids:   
pET 28 b(+) Protein overexpression plasmid, KanR Novagen 
pSPOmpF His-tagged OmpF overexpression 
plasmid, KanR 
This Study 






Table 2 – Primers Used in this Study 
Name: Purpose: Sequence: 
OmpF1 OmpF Sequencing Primer 5' - CTACCTATCGTAACTCCAACTTCT - 3' 
OmpR1 OmpF Sequencing Primer 5' - CCAAAGCCTTCGTATTCG - 3' 
NISF1 NIS Sequencing Primer 5' - TCATCCTGAACCAAGTGACC - 3' 
NISF2 NIS Sequencing Primer 5' - AGCTGTGACTGTGGAAGACC - 3' 
NISF3 NIS Sequencing Primer 5' - CCAAAGGAAGACACTGCCAC - 3'  
NISR1 NIS Sequencing Primer 5' - TTGGTCACAGCAGGGATGTC - 3' 
NISR2 NIS Sequencing Primer 5' - CGTAGATGAATGAGAGCCC - 3' 
NISR3 NIS Sequencing Primer 5' - CCTTCATACCACCCACGGT - 3' 
T7 pro  Sequencing  5' - TAATACGACTCACTATAG - 3' 
T7 term  Sequencing  5' - GCTAGTTATTGCTCAGCGG - 3'  
NIS 
Amp 1 
NIS amplification primer 5’- CATATGGAGGGTGCGGA - 3’ 
NIS 
Amp 2 












5' - TATCTCGAGGAACTGGTAAACGATACC - 
3' 
*See Appendix B for more detail on the development of these primers 
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RESULTS AND DISCUSSION 
Production of Perchlorate Reducing Cell-Free Extracts: 
Perchlorate reductase and chlorite dismutase are not commercially available. Several 
expression systems have been used to attempt to express perchlorate reductase from 
recombinant sources, but without success [43]. Chlorite dismutase has been overexpressed 
recombinantly, purified and shown to be active [37]. We are currently attempting to replicate 
this and obtain high concentrations of chlorite dismutase. In the meantime, cell-free extracts 
from perchlorate-reducing bacteria (PRB) were used as the source of these two proteins. 
Cell-free extracts have been shown to have high levels of perchlorate-reducing activity [49]. 
The perchlorate-reducing bacterium Azospira oryzae was grown as described in the 
materials and methods. Initially, the media in reference [39] was prepared as described in 
reference [49]. However, the resazurin used in [49] as a redox indicator seemed to hinder the 
growth of the organisms and it was difficult to get the strain to grow well and consistently. A 
comparison of growth in media with and without resazurin is shown in Figure 4. After many 
failed attempts, resazurin (included in reference [49], but not in reference [39]) was omitted 
from the media and the strain began to grow much better. Cultures were then inoculated in 
triplicate and optical density (at 600 nm) and perchlorate concentrations were measured over 
several days. Results are shown in Figure 5 b). As the cells grew, the perchlorate in the media 
was consumed, indicating that the cells were utilizing perchlorate. After a lag phase, the 
cultures grew to a maximum optical density measurement of approximately 0.65 Au and then 
exited log phase. The exit from the logarithmic phase seemed to correspond with the 
exhaustion of perchlorate, as measured by HPLC MS. DAPI stained images of the A.oryzae 
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Typical raw data results for a methyl viologen activity assay are shown in Figure 6. The 
baseline was recorded for 100 seconds and then perchlorate was injected into the cuvette to 
start the reaction (in Figure 6 note the sudden drop in absorbance around 100 seconds as the 
cuvette is removed to inject the perchlorate). The absorbance in the cuvette is then measured 
over time.  
The slope of the decline can be used to calculate the activity per Equation 1 [56]. One 
unit is defined here as: 1 µmol MV+ oxidized / min (note: reference [49] defines 1 U as 2 
µmol MV+ oxidized / min). Activities of these extracts were quite variable, ranging from 4 
U/mL to 40 U/mL. The variability of the extract activities may have been due to differences 
in preparation method: slight differences in the initial oxygen concentrations in the media, the 
timing of pelleting in the growth curve, or freezing of the cells prior to making cell extract. 
The activity measured previously was 3.45 U/mL [49], which is slightly lower than the 
activities measured here. This is due to the greater dilution of extracts used in their 
preparation method. Overall, the extract activities and preparation methods reproduced in my 
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As an alternative method to purify OmpF, a Histidine-tagged OmpF vector was 
created as shown in Figure 9. At the beginning of this study, access to an ultracentrifuge was 
not available and the procedure used for the Omp8 strain would have been difficult. To 
circumvent this problem, we created a Histidine-tagged OmpF plasmid to purify OmpF using 
affinity chromatography. OmpF was amplified as described in the materials and methods and 
ligated into the NdeI and XhoI restriction sites of the pET 28b(+) vector. This plasmid was 
sequenced and shown to be free of any errors (data not shown). Pilot expressions using this 
vector in BL21 (DE3) cells showed good overexpression of OmpF, as can be observed in 
Figure 10. This OmpF is slightly larger than the OmpF derived from Omp8, as two histidine 




Figure 9 – Construction of Histidine-Tagged OmpF Plasmid. The OmpF gene was PCR 
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used. Large materials such as vesicles do not fit inside the pores of the size exclusion media, 
and thus go through the column quickly, in what is termed the void volume. Smaller 
materials like proteins can enter the pores in the media and will thus go through the size 
exclusion column much more slowly. In these experiments, two sets of vesicles are made, 
one with OmpF and one without. As methyl viologen cannot enter the no OmpF vesicles, 
they should not have detectable activity. 
After incubation for a few days (the time needed to form vesicles), the cell-free 
extracts began to aggregate into larger material. The effect of this can be observed in Figure 
13. The “fresh” cell-free extract (run on a column immediately after ultracentrifugation) has 
only a single peak with a shoulder, whereas the cell extract after storage has an additional, 
earlier peak, representing aggregates that have formed and come off the column in the void 
volume. This presented a problem for the purification of perchlorate-reducing engineered 
vesicles, as these aggregates could not be resolved from the polymer vesicles using size 
exclusion. The presence of these aggregates created the potential for enzymatic activity in the 
vesicle fractions from sources other than the vesicles. For example, in an encapsulation 
experiment on 5/6/2010, 7.6 U/L of activity was detected in vesicles without OmpF, similar 
to the amount of activity detected in the OmpF vesicles (15.69 U/L). The source of this 
contaminating activity was thought to be the aggregates. Subsequent experiments, detailed 
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7/7/2010 no OmpF  12  NA  9896.1  0.71  24.3 
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CONCLUSIONS AND FUTURE WORK 
The goal of my work was to create an engineered vesicle capable of reducing 
perchlorate, and this goal was met. I successfully prepared the components of the system: a 
membrane transport protein (OmpF) and perchlorate-reducing cell extracts. In preparation for 
using a specific perchlorate transporter, we have also achieved heterologous expression of the 
NIS protein. There were several issues with the procedure used to make and assay vesicles, 
such as aggregate contamination and oxygen leakage, but those issues have been addressed. 
At present, vesicle activity can be consistently detected using the procedures developed in my 
work, showing the creation of engineered vesicles capable of reducing perchlorate.  
Now that these vesicles have been created, one may look towards the application of 
these vesicles. To be useable in a reactor, these vesicles will need to be immobilized onto a 
substrate. These vesicles are in the size range of a few hundred nanometers, a size that would 
be difficult to contain in a suspended-growth reactor. However, there is some precedent, as 
engineered vesicles have been immobilized on a glass substrate before [14]. Vesicles 
immobilized on spherical media could be packed into a flow through reactor for utilization as 
a pilot or full-scale reactor. One proposed reactor setup is illustrated in Figure 21. Vesicles 
could be immobilized onto beads at very high densities. These beads could then be packed 
into a flow-through reactor. As these vesicles would only contain the enzymes relevant to 
perchlorate degradation, the enzymes could be packed at much higher densities that would be 
possible in a conventional bioreactor. In addition, these reactors could utilize enzymes in 
conditions where they would not be expressed by bacteria and these reactors could safely 
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40 
extraneous material, one could tag these proteins and purify them using affinity 
chromatography. The yields using this method would be significantly increased as well. 
Chlorite dismutase has been expressed and purified recombinantly in the past, and work is 
ongoing to replicate this in our laboratory [37]. Purification of perchlorate reductase with 
similar methods has been attempted, but unsuccessfully. This is a very large protein with 
multiple subunits, and thus may be difficult to heterologously express [43]. If the perchlorate 
reductase cannot be expressed and purified heterologously, purification from its native host 
can be performed [49]. Combined with the heterologously purified chlorite dismutase, pure 
sources of these two enzymes could provide much higher enzyme concentrations and a better 
defined system than the cell-free extract utilized in this work. 
Perchlorate reductase could also be coupled to a non-protein catalyst encapsulated in 
these vesicles. Chlorite dismutase is part of the superoxide dismutase family and research is 
being conducted to find catalysts that perform the same function as the enzymes in this 
family [61]. Chlorite dismutase has a limited number of turnovers before the enzyme ceases 
to function [37]. Thus, this system could couple protected perchlorate reductase and an 
artificial chlorite dismutase catalyst to create a novel enzyme/catalyst system. 
Furthermore, this system could remove perchlorate using different sources of 
reducing power. Our study used methyl viologen as an electron donor due to its use in the 
literature for perchlorate kinetic assays, but other donors could be used. This could allow for 
the use of a cathode to act as a primary electron donor, reducing an electron shuttle that 
powers perchlorate reduction and obviating the need for large amounts of exogenous electron 
donor, as required in traditional biological perchlorate treatment. This has been attempted 
using a perchlorate bioreactor [62]. The addition of excess exogenous donor and the resulting 
regrowth potential in the distribution system is one issue that must be addressed in current 
perchlorate bioreactor designs. If a cathode is used as a donor, no residual exogenous donor 
remains, removing the risk of regrowth [62]. 
Using different enzymes, engineered vesicles could catalyze the removal of other 
contaminants. As a generalized system, one simply needs a source of enzyme, polymer, and 
membrane protein to make these vesicles. Technical hurdles must be overcome for sources of 
these materials to be commercially viable. However, engineered vesicle reactors have a 
number of advantages, such as the ability to utilize enzymes in conditions where they would 
not be expressed by bacteria and the ability to utilize genetically engineered proteins. As 
sources of polymer and recombinant enzymes become available, large-scale vesicle reactors 
could become a reality. My work has prepared the components of engineered vesicle reactors 
41 
and shown them to be functional. These components have been assembled in polymer 
vesicles and are active. These prototype vesicles can be used for the future development of 
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APPENDIX A: DETAILED PROTOCOLS 
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ENCAPSULATING CELL-FREE EXTRACT FROM 5000 ML OF AZOSPIRA 




100 mL Rikken Media 
5 L Rikken Media 
Azospira oryzae glycerol stock 
Stainless Steel Extruder 
Akta Prime 
Sephracyl 500-HR column 




Nutrient Agar Plate 
50 mM Phosphate Buffer pH 6.0 
Fisher Sonic Dismembrator 
Ultracentrifuge and 10.9 mL ultra centrifuge tubes 
Rotary Evaporator 
ABA3 Polymer 
20 mg/mL Proteinase K 
Microplate and microplate reader 
BCA protein assay kit (Pierce) 
 
Step 1: Streak Azospira oryzae to a nutrient agar plate. 
 
From a glycerol stock (labeled Azospira oryzae) in box labeled “SP Freezer stock” in the 
-80°C freezer, streak to a nutrient agar plate, and incubate at 30 deg C for 3 days. 
 
Step 2: Transfer a colony to 100 mL of anaerobic Rikken Media. 
 
Withdraw 0.5 mL of Rikken media from tube and transfer to a sterile microcentrifuge tube 
using a sterile needle and syringe. Pick a large colony from the plate using a sterile toothpick 
and transfer to the medium in the tube. Using a sterile needle, transfer the medium back to 
the larger tube and incubate at 30 deg C for 3-5 days until turbidity has developed in the 
media. 
 
Step 3: Inoculate 5 L bottles.  
 
Pour the starter culture into 5L bottles of Rikken Media. Cap with a rubber stopper. Incubate 
for 4-5 days at 30 deg C on a stir plate. When the OD600 is ≥ 0.6 (measure turbidity before 
pelleting), spin down the cells in the media in a centrifuge for 10 min at 6000 x g. Use pellets 
for cell-free extract preparation or freeze at -80 deg C for later use. For pelleting cells use the 
floor model centrifuge and tubes with purple caps. 
 
Step 4: Resuspend pellets from 5 L culture in a total of 10 mL 50 mM PBS at pH 6.0 with 
0.1 mg/L DNase in a 50 mL tube.  
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Step 5: Sonicate 3s on, 2 sec off for 3 min, with 5 min on ice in between. Set sonicator to ~ 
30 % amplitude. Collect Sample (Lys 1). 
 
Step 6: Centrifuge for 15 min at 5000 x g in 1.7 mL microcentrifuge tubes in a Fisher 
Legend Centrifuge at 4 deg C. Collect supernatant. 
 
Step 7: Centrifuge supernatant from step 6 for 1hr at 40,000 rpm in Ti 70.1 rotor. Use 
Beckman ultracentrifuge bottles and be sure bottles are balanced to within 0.01 g.  
 
Use supernatant in later steps of protocol (cell-free extract). Add protease inhibitor to the 
cell-free extract if desired. Collect Sample (Su 1). Be sure to avoid getting lipid material from 
pellet into supernatant when collecting supernatant. 
 
Step 8: Test enzyme activity of Su1 using the protocol for enzyme assays of perchlorate with 
10 uL of cell-free extract. 
 
Step 9: Hydrate film made using 200 mL flask. 
 
Form a film from 12 mg ABA 3 polymer using a rotary evaporator. Wash flask with soap and 
rinse with chloroform. Dissolve polymer in chloroform. Put flask onto rotary evaporator and 
remove chloroform first using a pressure of 150 mBar and then a pressure of 50 mBar until a 
film forms. Pull a full vacuum on the film for 4 hours. Add 1.5 mL cell-free extract as well as 
desired amount of OmpF (depending on molar ratio desired). Hydrate with stir bar for two 
days in fridge until polymer chunks are gone. Collect fraction (Hy 1) if desired. 
 
Step 10: Extrude. 
 
Spin down hydration mix for 1 min at 16,000 x g in microcentrifuge using a tabletop 
centrifuge. Use supernatant for extrusion. 
 
Extrude 1 time through a 1 micron filter and then 10 times through a 0.4 or 0.6 micron filter 
using extruder in Clark Lab. Do not let pressure go above 50 psi. Collect fraction (Hy 2) and 
measure perchlorate-reducing activity.  
 
Step 11: Treat with Protease. 
 
Add 5% by volume 20 mg/mL solution of proteinase K to extruded vesicle mix. Sample 
should become slightly less turbid as protein aggregates are broken apart. Let sit at room 
temperature for 1 hour before size exclusion. 
 
Step 12: Run vesicles on Sepharcyl 500 pressurized column. 
 
Equilibrate Column using 50 mM PBS buffer for 1 hr. Inject vesicles onto column and record 
UV absorbance.  
 
Size Exclusion Protocol: 
 
Set UV-lamp to “on”; go to manual run, set pressure limit to 0.38 mPa; clean loading loop 
tubing (2 ml volume) with DI, then buffer (take off port and clean with syringe in sink); start 
run and click prompts to get run going. 
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Pause flow rate before loading the vesicle solution; set valve to “load!”; add sample; 
set valve to inject; resume flow rate (up to 0.5 ml/min); set collect fraction to 5.0 ml (for 
cleaning tubing in advance). Collect first peak, as this is the void volume-vesicle fraction. 
 
Step 13: Measure activity of approximately 400 uL of vesicles. 
 
Use PROTOCOL FOR ENZYME ASSAYS OF PERCHLORATE to measure activities. 
 
Step 14: Quantify Size of vesicles using a 1:10 or 1:20 dilution of vesicles in buffer using 
DLS. 
 
Dilute samples 1:10 or 1:20 in buffer (e.g. 50 uL vesicles in 500 uL buffer) in a disposable 
sizing cuvette. Using zeta sizer, make 3 size measurements. Set material to polystyrene latex. 
 
Step 15: Measure protein concentration of cell extract batch, Hydration Mix (Hy2), and 
vesicles using BCA protein method, use a 1:10 to 1:20 dilution of the hydration mix and the 
cell extract batch. 
 




Kengen SWM, Rikken GB, Hagen WR, van Ginkel CG, Stams AJM (1999) Purification and 
characterization of (per) chlorate reductase from the chlorate-respiring strain GR-1. Journal 
of Bacteriology 181 (21):6706-6711. 
 
Rikken GB, Kroon AGM, van Ginkel CG (1996) Transformation of (per)chlorate into 
chloride by a newly isolated bacterium: reduction and dismutation. Applied Microbiology 




50 mM Phosphate Buffer, pH 6.0: 
6g NaH2PO4 H20 












100 mL Rikken Media 
5 L Rikken Media 
Azospira oryzae glycerol stock 
 
Step 1: Streak Azospira oryzae to a nutrient agar plate. 
 
From a glycerol stock (labeled Azospira oryzae) in box labeled “SP Freezer stock” in the 
-80°C freezer, streak to a nutrient agar plate, and incubate at 30 deg C for 3 days. 
 
Step 2: Transfer a colony to 100 mL of anaerobic Rikken Media. 
 
Withdraw 0.5 mL of Rikken media from tube and transfer to a sterile microcentrifuge tube 
using a sterile needle and syringe. Pick a large colony from the plate using a sterile toothpick 
and transfer to the medium in the tube. Using a sterile needle, transfer the medium back to 
the larger tube and incubate at 30 deg C for 3-5 days until turbidity has developed in the 
media. 
 
Step 3: Inoculate 5 L bottles.  
 
Pour the starter culture into 5L bottles of Rikken Media. Cap with a rubber stopper. Incubate 
for 4-5 days at 30 deg C on a stir plate. Make sure stir bar is rotating. When the OD600 is ≥0.6 
(measure turbidity before pelleting), spin down the cells in the media in a centrifuge for 10 
min at 6000 x g and use for cell-free extract preparation or freeze for later use. For pelleting 
cells use floor model centrifuge and tubes with purple caps. 
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Rikken Media for Azospira [39]: 
 
In 1 L Water (2 L) {5 L}: 
1.55 g K2HPO4 (3.1) {7.75} 
0.85 NaH2PO4 H2O (1.7) {4.25} 
1 g NaClO4 or 1.15 g NaClO4 H2O (2.3) {5.75} 
2 g NaCH3COO (4g) {10 g}: 
0.5 g (NH4)2HPO4 (1) {2.5} 
0.1 g MgSO4 7H2O (0.2) {0.5} 
0.02 g yeast extract (.04) {0.1} 
0.2 ml trace elements (0.4) {1 mL} 
0.17 mg Na2SeO4  
 
Mix together ingredients in order shown. 
Dispense in to smaller tubes if desired. 
Degass smaller tubes (100 mL) under N2 gas using a canula (30 min for 100 mL cultures). 
Flush headspace of smaller tubes (100 mL) with 80% N2 20% CO2 gas using a canula (6 min 
for 100 mL cultures). 
Add a stir bar into 5 L broth (5L broth is not degassed). 




Trace metal solution [63] 
1L     250 mL  
Ethylenediamine tetraacetic acid  50.0 g,    12.5 g 
ZnSO47H20      2.20  g,   0.55 g 
CaCl2-2H20      5.54 g,    2 g 
MnCl2-4H20      5.06 g,     1.265 g 
FeSO4-7H2O      4.99 g    1.248 g 
(NH4)Mo7024-4H2O    1.10 g,     0.275 g 
CuSO4*5H20      1.57 g    0.3925 g 
CoCl2.6H20      1.61 g    0.4025 g 
H20        250 mL    1000 ml.  
 
Add ZnSO4 and EDTH Adjust to pH, 6.0 with KOH. Allow time for these two to dissolve,  
add other components slowly, maintaining pH 6.0 with KOH. Solution should have a green 
color after everything dissolves. Autoclave. After sitting on bench for a few weeks, solution 
will turn purple. 
 
Nutrient Agar Plates: 
 
Beef Extract   3.0 g 
Peptone   5.0 g 
Agar    15.0 g 
 
1.  Suspend 23 g of the powder in 1 L of purified water. Mix thoroughly. 
2.  Heat with frequent agitation to completely dissolve the powder. 
3.  Autoclave at 121°C for 15 minutes. 
 
Procedure: 
Autoclave the agar, cool to 45-50°C and pour into Petri dishes. Allow to solidify for at least 
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Glycerol Stock “New Omp8” 
LB-Amp Plate 
2 L LB Broth 
20 mM Tris-CL pH 8.0 




Wheaton 7 mL Homogenizer 
Ultracentrifuge 
 
Day 1: Streak Plate. 
 
5 PM - Streak Omp8 (freezer stock labeled Omp8 in box labeled “SP Freezer Stocks”) to an 
LB-Amp plate, grow for 18+ hours. 
 
Day 2: Make Starter Cultures. 
 
12 PM - take plate out, immediately pick colonies and inoculate three 5 mL Starter cultures 
in LB-Amp. DO NOT STORE PLATE IN FRIDGE BEFORE MAKING STARTER 
CULTURES. Plate is often bad after going into the fridge. 
 
Day 3: Inoculate, Induce and pellet Omp8 Cells.  
 
6 am – Inoculate each of the 1 L LB fernbach flasks with 1 starter culture. Grow Until OD600  
0.5 to 0.8 AU (Approx 3-7 hours) at 37 deg C at 200-250 rpm. 
 
~12 pm – induce with 0.4 mM IPTG (0.0952 g IPTG per 1 L fernbach flask). Grow for 
another 6 hours at 37 deg C. 
 






Step 1: Lyse Cells. 
 
Resuspend cell pellet in 10 mL buffer per g cell pellet (20 mM Tris-Cl pH 8.0). 
 
Add 10 uL DNase I (1 U/uL) per 10 mL Buffer. 
 
Disrupt cells using a sonicator: 3 sec on 2 sec off for 5 min at 30% amplitude. Leave sample 
on ice during and for 5 min between cycles. Sonicate three times. 
 
Step 2: Add SDS and incubate. 
 
Add 1 mL 20% SDS per 10 mL cell suspension. Make fresh SDS every day. Sample should 
turn clear after addition of SDS. If not, sonicate for additional time. Incubate for 1 hr at 60°C 
with gentle stirring. 
 
Step 3: First Centrifuge cycle. 
 
Centrifuge at 40,000 x g (~17,000 rpm) using Type 70.1 rotor at 4°C for 60 min. 
 
Step 4: Preextraction. 
 
Keep 100 uL of supernatant for SDS-PAGE. Wash pellet with 20 mM phosphate buffer pH 
7.4 to remove residual SDS. Add 5 mL/g cell pellet 0.125% Octyl-POE in 20 mM phosphate 
buffer pH 7.4.  
 
Homogenize pellet using Wheaton 7 mL homogenizer. 
 
Shake for 1 hr at 37°C. 
 
Centrifuge at 40,000 rpm (~145,000 x g) at 4°C for 45 min using Type 70.1 Ti rotor. 
 
Step 5: Extraction. 
 
Keep 100 uL of supernatant for SDS-PAGE. Add 2 mL/g cell pellet 3% Octyl-POE in 20 
mM phosphate buffer pH 7.4.  
 
Homogenize pellet using Wheaton 7 mL homogenizer. 
 
Shake for 1 hr at 37°C. 
 
Centrifuge at 40,000 rpm (~145,000 x g) at 4°C for 45 min using Type 70.1 Ti rotor. OmpF 
is in the supernatant.  
 






2 g SDS 
Make up to 10 mL total volume. 
 
Heat to approx 70°C and stir until SDS is dissolved. 
 
20 mM Tris-Cl: 
 
In 200 mL: .48 g Tris base 
Adjust to pH 8.0 using HCL. 
 
20 mM phosphate buffer: 
 
Stocks to make 20 mM phosphate buffer: 
 
0.2 M Na2HPO4 x H2O (M=178.05 – 1.78 g/50mL) 
0.2 M NaH2PO4 x H2O (M=156.05 – 1.56 g/50mL) 
 




20 g Lennox LB Broth. 
 




LB amp plate: 
 
20 g Lennox LB Broth 
15 g Agar 
 
Dissolve in 1 L water. 
 
Autoclave, allow to cool, add 50 mg Amp. 
 









Anaerobic Cuvettes with 13 mm septa (SIGMA catalog number Z106496-100EA) 
Spectrophotometer  (to measure absorbance at 578 nm) 
Dithionite Solution (0.2 M) 
Perchlorate (1 M) 
 
Purge 10 mL assay mixture with N2 for 6 min beforehand to remove O2. Use Finneran lab 




Sample: hydration mix/cell extract/perchlorate reducing vesicles  
 
Negative control 1: Add 30 µL DI water in lieu of perchlorate + cell free extract 
Negative control 2: Add 30 µL 1M sodium perchlorate but no cell free extract 
 
Step 1: Prepare Assay Mixtures and Capped Cuvette 
 
Move degassed assay mixture, cuvettes, and septa inside anaerobic glove box. Pipette 2 mL 
assay mixture into cuvettes inside glove box. Cap with septa and screw cap and cuvette 
together tightly.  Move cuvette from glove box, and add desired volume of sample to 
cuvette for cell extract activity measurments. For vesicles, add vesicle mix before capping 
with septa and use spectrophotometer in Strathmann glove box. 
 
Place sample into spectrophotometer and blank at 578 nm. 
 
Assay mixture volume: 2 mL 
 
Components: 
50 mM Tris-Cl- Buffer 
0.5 mM MV 
20 µL enzyme mixture/cell fraction or approx 400 µL vesicle solution 
 




Dithionite solution (0.2 M) until absorbance of 1.5 is reached (Range of 1.3 to 1.8 should be 
fine, usually requires around 5 uL of dithionite). Sample should turn royal blue as dithionite 
is added. If measuring activity of vesicles, let sample sit for 5 min to scavenge any remaining 
oxygen and to decrease blank measurement. 
 
Step 3: Start reaction  
 




Add 20 µL chlorate or perchlorate (0.1 M) to samples and measure absorbance over 1-2  
min if measuring activity of hydration mix/cell extract. Log for 1000-5000 seconds if 
measuring activity of vesicles. 
 
Repeat with controls as desired. 
 
Step 4: Calculate perchlorate-reducing activity 
 
Use extinction coefficient of 13.1 mM-1 for MV and Equation 1. 
 





Grzelakowski M, Onaca O, Rigler P, Kumar M, Meier W (2009) Immobilized  
 
Protein-Polymer Nanoreactors. Small 5 (22):2545-2548. 
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Preparation of Solutions: 
Assay Mixture: 
Make 1 M Tris-Cl 
 
Tris-HCl is a solution frequently used in biochemistry made from Tris base and concentrated 
hydrochloric acid (HClaq). To make 1 mol/L Tris-Cl dissolve 121.1 g of tris base in 700 ml 
of double distilled water, bring to desired pH with concentrated HClaq (usually 7.5 or 8.0), 
add double distilled water to 1 L, filter with 0.5 μm filter, autoclave, and store at room 
temperature. 
 
Make 50 mM Tris-Cl- Buffer, MW = 121.13, = 12.5 mL 1 M Tris in 250 mL. 
Adjust to pH 7.5. 
 
Add Methyl Viologen (MV), MW = 257.16, (0.5 mM) = 0.032 g in 250 mL (Adjust for 













Kengen SWM, Rikken GB, Hagen WR, van Ginkel CG, Stams AJM (1999) Purification and 
characterization of (per) chlorate reductase from the chlorate-respiring strain GR-1. Journal 
of Bacteriology 181 (21):6706-6711. 
  
61 





Tris Tween Buffered Saline 
Filter Paper 
Membrane (Nitrocelluose or PVDF) 
Antibodies 




Step 1: Transfer Blotting 
 
1. Prepare the transfer buffer. (Using buffer chilled to 4°C will improve heat dissipation.) 
 
2. Cut the membrane and the filter paper to the dimensions of the gel or use precut 
membranes and filter paper. Always wear gloves when handling membranes to prevent 
contamination. Equilibrate the gel and soak the membrane, filter paper, and fiber pads in 
transfer buffer (15–20 min depending on gel thickness). It helps to soak the membrane in 
methanol first and then in water.  
 
3. Prepare the gel sandwich. 
Place the cassette, with the gray side down, on a clean surface. 
Place one pre-wetted fiber pad on the gray side of the cassette. 
Place a sheet of filter paper on the fiber pad. 
Place the equilibrated gel on the filter paper.* 
Place the pre-wetted membrane on the gel.* 
Complete the sandwich by placing a piece of filter paper on the membrane.* 
Add the last fiber pad. 
 
* Removing any air bubbles which may have formed is very important for good results. Use 
a glass tube or roller to gently roll out air bubbles. 
 
Current flows from the gray to the red (black to red) so that the protein comes out of the gel 
and onto the membrane. 
 
4. Close the cassette firmly, being careful not to move the gel and filter paper sandwich. 
Lock the cassette closed with the white latch. 
 
5. Place the cassette in module. Repeat for the other cassette. 
 
6. Add the frozen blue cooling unit. Place in tank and fill to the "blotting" mark on the tank. 
 
7. Add a standard stir bar to help maintain even buffer temperature and ion distribution in 
the tank. Set the speed as fast as possible to keep ion distribution even. 
 
8. Put on the lid, plug the cables into the power supply, and run the blot.  
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A 30 V current run overnight (~16 hours) worked for us in the past for transfer.  
 
9. Upon completion of the run, disassemble the blotting sandwich and remove the membrane 
for development. Clean the cell, fiber pads, and cassettes with laboratory detergent and rinse 
well with deionized water. 
 
 
Step 2: Developing  
 
1. Take out membrane mark the top (active) side of the membrane to make sure reaction is 
being conducted on the correct side of the membrane. 
 
2. Soak the membrane in 30 ml blocking buffer (TTBS+ 0.9 g non-fat dry milk (1.5%))  
for 45 minutes to 1 hour. 
 
3. Incubate with 30 ml TTBS + anti His antibody –primary antibody (1:500 ratio, 60 uL) or 
anti NIS antibody –primary antibody (1:200 ratio, 150 uL) +  0.3 g non-fat dry milk 
(0.5%))  for 60 min.  Antibody volume – 60 uL or 150 uL depending on antibody. Save 
TBS/antibody mix in fridge. 
 
4. Wash membrane in TTBS with gentle shaking for 5 min X 3. 
 
5. Incubate membrane in 30 ml TTBS + secondary antibody  (1:1000 ratio, 30 uL) - 30 
microL of secondary antibody + 0.3 g non-fat dry milk (0.5%)) for 60 min. Save 
TTBS/antibody mix in fridge. 
 
6. Wash membrane in TTBS with gentle shaking for 5 min X 3. 
 





1) Samples were run two ways, one as described here and another in which membranes 
were blocked overnight and the primary anti-His antibody was incubated for 5 hours 
before washing. 
2) Blocking with a mix of BSA and milk and overnight seems to help (1.5% each). The 
same mix should be used for primary and secondary antibodies. Overnight blocking, 
longer primary antibody incubation time (2-3 hours) and only 45 min for secondary 
antibody incubation are other conditions that seem to work. Instead of 3 x 5min 
washes in between the primary and secondary antibody incubation, 6 x 5min seemed 





Towbin transfer Buffer (w SDS)  
25 mM Tris            3.03 g Tris 
192 mM glycine     14.4 g glycine 
20% methanol 
1g SDS 
Bring to 1 L. 
 
pH should be around 8.3. 
 
TTBS (Tris Tween Buffered Saline) 
 
20mM Tris, pH 7.5   20 ml 1 M Tris  (or 3.15 g Tris) 
0.1 M NaCl   100 ml 1 M NaCl (or 5.85 g NaCl) 
0.1% Tween 20  1ml Tween 20 






























































































































































































































































AGGTTGCGCCCACTTCAAAGTAGTTCACCAGATCAACATCAC 3’  
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Upstream Primer Complementary Sequence (just chose beginning of 
OmpF sequence, see highlighted region in OmpF sequence): 
ATGATGAAGCGCAATATTCTG 
  
Add Nde I Restriction Site (CA^TATG); upstream bases to allow for 




Number of base pairs of total primer: 27 
Tm = 58˚C  
GC = 41% 
 




Tm = 49˚C  
GC = 39% 
 









Downstream primer anti sense sequence (used primer selection tool 
from ApE): 5’ GAACTGGTAAACGATACC 3’(See reverse complement 
sequence after stop codon above) 
 
Add XhoI Restriction sequence for downstream (CTCGAG), 3 base pairs 
to allow for restriction (TAC)  
 
Final Primer Complete Sequence: 
TATC^TCGAGGAACTGGTAAACGATACC 
 
Number of base pairs: 27 
Tm = 59˚C  
GC = 44% 
 





Tm = 48˚C  
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